List view / Grid view
The UK’s Medicines and Healthcare products Regulatory Agency (MHRA) has reported that Evusheld, developed by AstraZeneca, has been granted approval to help protect against the effects of COVID-19.
A study shows terahertz light creates twisting vibrations in biomolecules, enabling the analysis of their compositions and structures.
Pfizer is voluntarily recalling Accuretic tablets and two generic high blood pressure treatments, due to levels of nitrosamine above ADI.
![Catalent logo on website through a magnifying glass [Credit: Pavel Kapysh/Shutterstock.com].](https://www.europeanpharmaceuticalreview.com/wp-content/uploads/Catalent-300x278.jpg)
![Catalent logo on website through a magnifying glass [Credit: Pavel Kapysh/Shutterstock.com].](https://www.europeanpharmaceuticalreview.com/wp-content/uploads/Catalent-e1647945626125.jpg)
The completed modernisation of Catalent’s facility in Limoges, France, will support the development of early phase and small-scale commercial biologic drugs.
An early halt has been called to a major kidney drug trial following positive results for patients with chronic kidney disease (CKD).
Investigational drug Lambda reduced risk of COVID-19-related death in one of the largest studies of its kind to date.
Pfizer’s oral COVID-19 treatment nirmatrelvir will be produced by 35 generic manufacturers to increase supply for low- and middle-income countries.
Lynparza® (olaparib) is the first PARP inhibitor to demonstrate overall survival benefit in early breast cancer, according to new data.
Unveiling its Medicine Supply Map, the US Pharmacopeia (USP) showed how reliant the US pharma supply chain is on Indian API manufacturers.
New data shows that patients taking Aduhelm® (aducanumab-avwa) had significant reductions in tau and amyloid beta after nearly 2.5 years.
AbbVie releases promising results from its Phase III trial of atogepant (Qulipta™) for preventative treatment of chronic migraine.
New data demonstrates the long-term safety and efficacy of Evrysdi® (risdiplam) in a broad population of people with spinal muscular atrophy (SMA).
The Phase IIa influenza-challenge study will enrol 123 healthy adults and support the development of INNA-051 as a pan-antiviral nasal spray.
The investment will advance the development of a subcutaneous Sarclisa (isatuximab) formulation for multiple myeloma (MM) treatment.
Pipe-307 demonstrated linear pharmacokinetic (PK) data consistent with pre-clinical modelling and was generally well tolerated at all doses in 70 healthy adult volunteers.
